Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4128 - Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Breast Cancer

Presenters

Elsa Curtit

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

E. Curtit1, F. Bazan1, L. Chaigneau1, G. Mouillet1, E. Dobi1, L. Mansi1, N. Meneveau1, M. Paillard1, G. Meynard1, E. Klajer1, C. Villanueva2, P. Montcuquet1, X. Pivot3, L. Cals4

Author affiliations

  • 1 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 2 Medical Oncology, Centre de Cancérologie du Grand Montpellier, 34070 - Montpellier/FR
  • 3 Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 4 Medical Oncology, CH Mende, 48000 - MENDE/FR
More

Resources

Abstract 4128

Background

More than 50% of metastatic breast cancer patients experience bone metastases over the course of disease and around 15% of cases have metastases confined to the skeleton at metastatic presentation. The aim of this study was to access the overall survival of breast cancer patients with bone-only metastases at presentation.

Methods

Among 907 patients, we identified from our prospective computerized database 123 patients with bone-only metastases at diagnosis of metastatic breast cancer. We retrospectively collected data from the patients’ files.

Results

The median overall survival was 8,3 years (CI 95% 6,7-10,3) and 73% and 41% of patients were alive at 5 and 10 years, respectively. No multivariate model with factors identified at presentation was able to predict overall survival length. Sixty per cent of patients developed visceral metastases over the time and the median interval between the diagnosis of bone metastases and the occurrence of visceral metastases was 28 months (4 - 193). In multivariate analysis, negative progesterone receptor status was associated with the occurrence of visceral metastasis (HR = 2,4; p = 0,03). Eleven per cent of patients had a solitary bone metastasis; 67% of patients developed axial metastases and 41% long bone metastases.

Conclusions

Breast cancer patients with bone-only metastases at presentation of metastatic disease might form a distinct clinical entity among metastatic breast cancer patients with a favorable prognosis and a prolonged overall survival. No prognostic factors identified at the presentation of the disease were able to predict very long survivors. Further investigations on these tumors biology and clinical trials dedicated to this population are required.

Clinical trial identification

Legal entity responsible for the study

CHRU Besançon.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.